Ibopamine
Executive Summary
Italian firm, Zambon, regains rights to the inotropic agent from SmithKline, which has decided not to develop the congestive heart failure drug. SmithKline was in late-Phase III studies on the compound. Ibopamine is one of three compounds Zambon has targeted for development in the U.S. through establishment of a new U.S. affiliate.